Clinical Trials Logo

2019 Novel Coronavirus clinical trials

View clinical trials related to 2019 Novel Coronavirus.

Filter by:
  • None
  • Page 1

NCT ID: NCT04731051 Not yet recruiting - Clinical trials for 2019 Novel Coronavirus

The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients

Start date: March 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in hospitalized cancer patients with COVID-19. King Hussein Cancer Center (KHCC) is the study sponsor, and the study will be conducted at KHCC COVID-19 wards. Approximately 28 cancer patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be enrolled and randomized 3:1 to the treatment and control arms where they will receive ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm where treatment will follow KHCC SOC.

NCT ID: NCT04334967 Suspended - COVID-19 Clinical Trials

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Start date: March 30, 2020
Phase: Phase 4
Study type: Interventional

This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19

NCT ID: NCT04246242 Not yet recruiting - Clinical trials for 2019 Novel Coronavirus

A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)

Start date: January 25, 2020
Phase: Phase 4
Study type: Interventional

Objective To determine the efficacy and safety of arbidol in patients with 2019 Novel Coronavirus (2019-nCoV).Methods Patients with 2019-nCoV were divided into three groups according to randomized double-blinded controlled clinical trial principle.Patients in three groups were administrated with arbidol,200mg,tid or arbidol,400 mg,tid or not for 5 days respectively. Other antiviral and comprehensive treatments of the three groups of patients are consistent. Then investigators will compare the first outcome: 28-day mortality, and secondary outcome: ICU hospitalization time, mechanical ventilation time, Hospitalization costs, antibiotic use costs, SOFA scores, CURB-65 scores, APACHE scores, and other clinical indicators.